Alivus Life Sciences share price
You have to be logged in to add this to Watchlist.- ₹1,011.00(-0.83%)July 11, 2025 15:28:00 PM IST
- NSE
- BSE
- Vol : 84.00K (NSE + BSE)Last 20 day avg : 85.84 K
Alivus Life Sciences is trading -0.83% lower at Rs 1,011.00 as compared to its last closing price. Alivus Life Sciences has been trading in the price range of 1,038.05 & 1,010.90. Alivus Life Sciences has given 3.94% in this year & -1.06% in the last 5 days. Alivus Life Sciences has TTM P/E ratio 27.31 as compared to the sector P/E of 22.90.There are 3 analysts who have initiated coverage on Alivus Life Sciences. There are - analysts who have given it a strong buy rating & - analysts have given it a buy rating. - analysts have given the stock a sell rating.The company posted a net profit of 141.87 Crores in its last quarter.Listed peers of Alivus Life Sciences include Caplin Point Laboratories (-1.17%), Sanofi India (-1.40%), Alivus Life Sciences (-0.83%).The Mutual Fund holding in Alivus Life Sciences was at 3.59% in 31 Mar 2025. The MF holding has increased from the last quarter. The FII holding in Alivus Life Sciences was at 6.57% in 31 Mar 2025. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
Updated on Jul 12, 2025, 12:53 AM UTC
- Dividend YieldLower than industry0.48Annual dividends as a percentage of the stock price.
- P/B4.53The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values26.33Price-to-earnings ratio based on trailing 12-month earnings
- BetaHigh volatility1.23Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.02The debt-to-equity ratio, indicating a company's financial leverage.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is profitable- The company's revenue grew in March quarter by 21.05% from Rs 649.55 crore to Rs 536.60 crore, year-on-year
- The company has grown its March quarter profit by 44.86% from Rs 97.94 crore to Rs 141.87 crore, year-on-year
The debt to equity of the company is higher than the industry median- Company can comfortably pay off its interest obligations with its earnings
- R1
- 1,041.48
- R2
- 1,080.27
- R3
- 1,110.03
- S1
- 972.93
- S2
- 943.17
- S3
- 904.38
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Caplin Point Laboratories | Moderately Bearish | 2,018.20 | -1.17 | 15,394.47 | 28.50 | 5.33 | 0.27 | 0.10 |
| Sanofi India | Moderately Bearish | 5,920.65 | -1.40 | 13,609.52 | 41.21 | 16.32 | 1.92 | 1.63 |
| Alivus Life Sciences | Bearish | 1,011.00 | -0.83 | 12,400.28 | 26.14 | 4.49 | - | 1.81 |
| Granules India | Bearish | 468.90 | -1.10 | 11,358.61 | 24.86 | 3.2 | 0.31 | 12.67 |
| Marksans Pharma | Neutral | 254.60 | -0.88 | 11,550.93 | 30.89 | 4.77 | 0.23 | 10.67 |
- Promoter(s) holds a high stake in the company at 74.99%
- Promoter(s) have decreased the stake in the company in last 12 months
- FIIs are invested in this company
- FIIs holding has decreased by 0.17 percentage points from previous quarter
- Mutual Funds holding has increased by 0.36 percentage points from previous quarter
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-05-15 | Audited Results & Final Dividend |
| 2025-01-23 | Quarterly Results |
| 2024-10-24 | Quarterly Results |
| 2024-07-25 | Quarterly Results |
| 2024-04-25 | Audited Results |
- IndustryBiotechnology & Drugs
- ISININE03Q201024
- BSE Code543322
- NSE CodeALIVUS
Alivus Life Sciences is trading at 1011.00 as on Fri Jul 11 2025 09:58:00. This is -0.83% lower as compared to its previous closing price of 1019.45.
The market capitalization of Alivus Life Sciences is 12400.28 Cr as on Fri Jul 11 2025 09:58:00.
The 52 wk high for Alivus Life Sciences is 1335.00 whereas the 52 wk low is 821.00
Alivus Life Sciences can be analyzed on the following key metrics -
- TTM P/E: 27.31
- Sector P/E: 22.90
- Dividend Yield: 0.49%
- D/E ratio: 0.02
Alivus Life Sciences reported a net profit of 485.63 Cr in 2025.
The Mutual Fund Shareholding was 3.59% at the end of 31 Mar 2025.